Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79714.180.1583%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Harvard Bioscience Inc

HBIONASDAQ
Trade with Public
Trade with Public
$8.02
0.020.25%
At close: Sep 4, 5:00 PM EST
$8.18
0.162%
After Hours: Sep 1, 7:50 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Harvard Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Harvard Bioscience (HBIO).

Price Target Range — 5 Quarters

Analyst Consensus

Consensus RatingSpeculative BuyAvg. Consensus PT$5Upside to Avg. PT-35.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026BenchmarkBruce D. JacksonPT RaiseSpeculative Buy$6→$8
Mar 16, 2026BenchmarkBruce D. JacksonPT RaiseSpeculative Buy$1→$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.
Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $0.6 to $6.
Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.
Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $3 to $2.
Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $4.5 to $3.
Benzinga Newsdesk

PRO
Keybanc Downgrades Harvard Bioscience to Sector Weight

Keybanc analyst Paul Knight downgrades Harvard Bioscience (NASDAQ:HBIO) from Overweight to Sector Weight.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved